Piramal Pharma Limited has released its financial results for the first quarter of FY26, reflecting a mixed performance across its business segments. While overall revenue saw a slight dip, strategic initiatives and operational efficiencies helped cushion the impact of inventory challenges and macroeconomic pressures.
Key highlights from the results:
1. Financial performance overview
- Revenue from operations stood at ₹1,934 crore, down 1 percent year-on-year from ₹1,951 crore
- EBITDA declined 26 percent to ₹165 crore, with margins narrowing to 9 percent from 11 percent in Q1FY25
- Net profit after tax improved slightly to a loss of ₹82 crore, compared to ₹89 crore in the same quarter last year
- Exceptional income of ₹21 crore was recorded from insolvency proceeds related to a third-party supplier
2. Segment-wise performance
Contract Development and Manufacturing Organization (CDMO)
- Revenue fell 6 percent to ₹997 crore due to destocking in a large on-patent commercial product
- Excluding destocking, base business showed mid-teen growth, led by overseas facilities
- Cost optimization and operational excellence initiatives supported profitability
- USFDA inspection at Aurora (Canada) facility concluded with zero observations
- Groundbreaking for capacity expansion at Lexington (US) facility to boost sterile injectable capabilities
Complex Hospital Generics (CHG)
- Revenue rose marginally to ₹637 crore, up 1 percent year-on-year
- Inhalation anesthesia segment faced slower growth due to timing of institutional orders
- USFDA approved Digwal (India) facility for Sevoflurane API and finished products
- Intrathecal therapy sales dipped due to shipment timing, with recovery expected in Q2
- Injectable anesthesia and pain management initiatives underway to resolve supply constraints by FY27
- Neoatricon launched in select EU markets, with broader rollout planned in Q2
Piramal Consumer Healthcare (PCH)
- Revenue surged 15 percent to ₹302 crore
- Power brands grew 18 percent year-on-year, contributing 49 percent of total PCH sales
- E-commerce sales jumped 41 percent, now accounting for 23 percent of PCH revenue
- Seven new products launched during the quarter
- Media and promotional investments represented 13 percent of PCH sales
3. Operational and strategic updates
- Net-debt to EBITDA ratio stood at 2.6x, indicating stable leverage
- ESG rating of 61 assigned for FY24 by NSE Sustainability Ratings and Analytics Limited
- Management reaffirmed long-term goal of achieving US$2 billion revenue, 25 percent EBITDA margin, and high-teen ROCE by FY2030
4. Market context and outlook
- The company acknowledged near-term challenges including uneven biotech funding and delayed decision-making in early-stage development projects
- Despite these headwinds, Piramal Pharma remains optimistic about growth in CHG and consumer segments for the remainder of FY26
- The Lexington expansion and continued regulatory compliance are expected to strengthen its global footprint
Source: PR Newswire, July 28, 2025
